measurement of bona fide ciliary signals in past work would have been difficult.
For the Ca 2+ -mechanosensation model to make sense physiologically, the location and timing of Ca 2+ influx would connect an observed signal to the physiological effect. For example, observations of fluid flow, ciliary bending, Ca 2+ influx and water transport in the collecting duct would have to be temporally and spatially linked. Delling and colleagues find no evidence of either the mechanical changes or the appropriate Ca 2+ signals in this setting, thus disputing this model. Although it is hard to categorically disprove a signalling hypothesis, the quality of the authors' work sets a high bar for any future study that supports ciliary mechanosensation.
Researchers must now find another channel. However, another study 12 by the current group indicates that the strong Ca 2+ signals observed in cilia do not require PKD1 or PKD2, but rather the related proteins PKD1L1 and PKD2L1, underscoring the fact that we understand neither the breadth of ciliary Ca 2+ signalling nor the fundamental pathways in which channel proteins such as PKD2 function.
Cells of the proximal collecting duct make up the kidney tubules involved in anti diuretic (urination-reducing), hormone-stimulated water transport. Malfunction of cilia in these cells is thought to be involved in watertransport-driven swelling of the collecting ducts and cysts in cystic kidney diseases. Delling et al. examined collecting-duct cilia using a flow chamber to approximate urinary flow rates and to cause varying degrees of ciliary bending, but observed no effects on Ca 2+ signalling. Occasionally, Ca 2+ signals were generated by damaging the cilia, and this would explain the discrepancy between these data and older work. Indeed, without modern sensors and control markers, 1 find that, contrary to this hypothesis, ciliary bending in response to force does not open Ca 2+ channels. Instead, the authors propose that the Ca 2+ influx observed in previous experiments might have been due to diffusion from the cell body, or to damage to cilia in response to extreme levels of force. T cells sense foreign invaders, including tumour cells, through nanoclusters of T-cell receptor (TCR) proteins on the cell surface. With the help of proteins called adaptors, TCRs then initiate an intracellular signalling cascade that leads to T-cell activation. The ability of cholesterol to enhance this activation has long been known, and probably arises from the sterol's role in organizing the cell membrane in which TCRs are embedded 4 . Cholesterol synthesis can be a limiting factor for T-cell growth, and increasing cholesterol biosynthesis enhances T-cell responses 5 . However, there are currently no therapies that increase cellular cholesterol.
CANCER IMMUNOTHERAPY

Killers on sterols
The enzymes acetyl-CoA acetyltransferase 1 (ACAT1) and ACAT2 generate cholesterol esters that are used for storage and inter cellular transport of the sterol, rather than contributing to cell membranes 6 . The liver and gut express ACAT2, whereas most cells, including T cells, express ACAT1. Yang et al. genetically modified mice such that their T cells lacked ACAT1. T cells developed normally in these micea finding that might be explained by the fact that developing T cells express higher levels of ACAT2 than do mature cells Yang et al. went on to show that the TCR nanoclusters on the surface of sterol-enhanced killer T cells were larger than those in wildtype cells. Formation of the immunological synapse -the point of embrace between the T cell and tumour cell -also occurred more quickly in enhanced cells than in wild-type cells, as did the release of toxins into the synapse. Immunological-synapse formation is necessary for the destruction of the tumour and its associated infrastructure 8 , and rapid synapse formation enhances the impact of toxin release 9 . The authors found that several signatures of T-cell activation, in particular phosphorylation of an adaptor protein called linker of activated T cells (LAT), were enhanced in ACAT1-deficient killer T cells. LAT has a lipid modification that ensures that it attaches to cholesterol-rich membrane regions, forming nanoclusters that join with TCRs to create signalling microclusters 10 . Increased cholesterol levels boosted the size of these signalling assemblies and thus enhanced T-cell responsiveness in ACAT1-deficient mice (Fig. 1) .
Yang et al. transferred antitumour, ACAT1-deficient killer T cells into a mouse model of cancer -an approach similar to adoptive immunotherapy approaches used in the clinic. Compared with wild-type killer T cells, the sterol-enhanced T cells provided the host with greater protection against the tumour. This result suggests that genetically engineering killer T cells from patients to delete ACAT1 might be a useful component of future immuno therapy approaches.
Can pharmacological inhibition of ACAT with a small molecule achieve similar benefits to genetic mutation? Avasimibe is a non-selective ACAT inhibitor that has been proven safe for short-term treatment in humans 11 . However, it failed to treat cardiovascular disease, for which it was originally developed, and so has yet to be approved for widespread human use. Nonetheless, it can be used in clinical trials, and has the advantage of being administered in a convenient pill. Yang et al. found that the effects of avasimibe mimicked those of ACAT1 deletion in vitro, and the drug significantly increased survival in mouse models of melanoma and lung cancer.
Yang and colleagues next combined avasimibe with a clinically approved checkpoint-blockade antibody called α-PD-1, which enhances immunological-synapse formation 12 . Drugs based on the α-PD-1 antibody have been approved for use in humans to treat lung cancer, kidney cancer and melanoma
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. Avasimibe acted additively with α-PD-1 in the authors' animal models, indicating that the two drugs promote synapse formation and tumour destruction through different and complementary mechanisms (Fig. 1 ).
Many people with cancer fail to respond to checkpoint-blockade drugs, so there is still room for improvement of this breakthrough therapy. Therefore, it is exciting to speculate that Yang and colleagues' basic observations and preclinical data might be a first step towards a pill for boosting killer T cells as part of anticancer and antiviral therapies. ■ Michael L. Dustin 3 used the drug avasimibe to inhibit the protein acetyl-CoA acetyltransferase 1 (ACAT1), which converts cholesterol to cholesterol ester. This inhibition increases cholesterol levels in the cell membrane of killer T cells, promoting clustering of T-cell receptors (TCRs) that bind to antigens presented on the surface of tumour cells. Higher levels of membrane cholesterol also promote activating phosphorylation (P) of an adaptor protein called linker of activated T cells (LAT), which acts with TCRs to transduce the tumour-cell signal and increases the speed at which the T cell and tumour cell form a point of embrace called the immunological synapse. Together, these factors promote the release of toxin molecules that trigger tumour-cell death. The T-cell protein PD-1 acts as an inhibitory checkpoint of this immune response by interacting with the tumour-cell protein PD-L1 to attenuate synapse formation. The authors found that avasimibe acts additively with α-PD-1 antibodies that block this checkpoint to reduce tumour growth and prolong survival in mouse cancer models.
